Go
HomeAlzheimer's Daily NewsThe Alzheimer's StoreAlzheimer's LibraryWandering
Alzheimer's Daily News > Alzheimer's Daily News Archive > News Archieve 2010 > February, 2010 > February 2, 2010


Subscribe to The
Alzheimer's Daily News

 
Enter your e-mail address in the box to join.




February 1, 2010
February 2, 2010
February 3, 2010
February 4, 2010
February 5, 2010
February 8, 2010
February 9, 2010
February 10, 2010
February 11, 2010
February 12, 2010
February 15, 2010
February 16, 2010
February 17, 2010
February 18, 2010
February 19, 2010
February 23, 2010
February 24, 2010
February 25, 2010
February 26, 2010


Spongiform Brain Diseases Caused by Aberrant Protein
(Source: Ohio State University) - Scientists have determined how a normal protein can be converted into a prion, an infectious agent that causes fatal brain diseases in humans and mammals.


Study to Expand Safety Profile for Dementia Drug Davunetide
(Source: Allon Therapeutics) - Allon Therapeutics announced that patient enrollment has begun for a human clinical trial to broaden the demonstrated safety range and pharmacokinetic profile of its lead neuroprotective drug davunetide.


Antidepressants May Improve Cognitive Function after Stroke
(Source: American Medical Association) - Patients who received the antidepressant escitalopram following a stroke appeared to recover more of their thinking, learning and memory skills than those taking placebo or participating in problem-solving therapy, according to a report.


A New 'Alzheimer's' Laboratory Rat Model
(Source: Alzheimer Research Forum) - Bigger, smarter, and more amenable than mice to the imaging techniques that are rapidly becoming indispensable in Alzheimer's research, rats could be a valuable model for studying AD. Their major downside, however, is that they are about five times more expensive to maintain than mice.


Project Lifesaver Offering Grants for New Programs and Families
(Source: Project Lifesaver) - Project Lifesaver International, a non-profit organization that helps rescue individuals who are prone to wander due to Alzheimer's disease, autism and other cognitive disorders, recently received federal assistance from the U.S. Department of Justice to expand its program throughout the country.